Back to results
US 2009/0022823 A1Published application
Methods for Administering Active Agents to CYP3A4 Sensitive Patients
AssigneeAlkermes, Inc.
InventorsElliot Ehrich, Trevor Mundel
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAlkermes, Inc.
InventorsElliot Ehrich, Trevor Mundel
Estimating the term…
The present invention relates, in part, to the discovery that parenterally administered extended release formulations possess an unexpected advantage in treating patients possessing active CYP 3A4. This advantage is particularly beneficial where the individual is concomitantly administering a CYP 3A4 inhibitor or is in risk of doing so. Thus, the invention relates to a method for treating individuals possessing a functional CYP3A4 gene with an active agent metabolized by CYP3A4 comprising parenterally administering the active agent in a first extended release formulation in a first administration and the formulations for use in such methods. The invention further includes a method for preventing adverse drug reactions in individuals possessing a functional CYP3A4 gene with an active agent metabolized by CYP3A4 comprising parenterally administering the active agent in a first extended release formulation in a first administration.
A method for treating individuals, wherein the individuals (a) possess a functional CYP3A4 gene, (b) are being administered a CYP3A4 inhibitor and (c) are in need of an extended administration of an active agent metabolized by CYP3A4 comprising parenterally administering the active agent in an extended release formulation wherein the extended release formulation releases the active agent over a period of at least about 7 days.
A method for treating individuals, wherein the individuals
Dependencies are inferred from the claim text.